{
}
Insilico Medicine, an AI-driven drug discovery company, has raised $110 million in its Series E funding round, achieving a valuation of over $1 billion. The investment, led by Value Partners Group, will enhance its AI platform and support the clinical development of Rentosertib for idiopathic pulmonary fibrosis, which has completed Phase IIa trials.With a pipeline of 30 drug assets, including 10 approved by the US FDA for investigational use, Insilico also licenses its assets to firms like Fosun Pharma and Exelixis, securing contracts worth approximately $3.5 billion. The company is advancing its proprietary AI system, “pharma.ai,” and developing humanoid robots to automate lab processes.
Exelixis, Inc. reported a 14.3% year-over-year revenue increase, reaching $539.5 million, with a quarterly EPS of $0.40, surpassing estimates. Insider transactions revealed a significant sale by EVP Patrick J. Haley, who sold 41,588 shares, reducing his stake by 12.59%. Hedge funds hold 85.27% of the company's stock, with analysts maintaining a "Moderate Buy" rating and a target price averaging $36.06.
ICER's annual report criticizes major pharmaceutical companies, including Gilead, J&J, and Novartis, for "unsupported" price increases on ten drugs, leading to an additional $815 million in U.S. payer costs last year. Gilead's Biktarvy topped the list with a 5.9% hike, costing $359 million. Companies have pushed back, claiming ICER's methodology overlooks crucial clinical evidence and could hinder the development of new treatments.
Exelixis, Inc.
Companies
| Symbol | EXEL |
| Name | Exelixis, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | Alameda |
| Zipcode | 94502 |
| Website | http://www.exelixis.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Insilico Medicine secures 110 million dollars in series E funding round
United States Dollar
FOSUN PHARM
Eli Lilly & Co
Exelixis, Inc.
Value Partners Group Ltd
Orbimed Advisors LLC
USA
CHN
Eli Lilly
Show more
04:50 13.03.2025
exelixis executive vice president reduces stake amid insider selling trends
15:36 28.01.2025
icER highlights unsupported price hikes by major pharmaceutical companies
United States Dollar
Johnson & Johnson
Exelixis, Inc.
Gilead Sciences, Inc.
Pfizer Inc.
Novartis AG
USA
Show more
20:24 12.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Supply Chain Management
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Industry Mergers & Acquisitions
Retail and Consumer Goods
Financial Scams and Security
Emerging Startups
Workplace Trends
Venture Capital Investments
Finance Mergers & Acquisitions
Cryptocurrency Trends
Funding Rounds & Investments
Fintech Startups
Energy Sector Developments
CEO Changes
Market Analysis and Predictions
Stock Market Updates
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Adobe Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Vietnamese Đồng
New Taiwan Dollar
United Arab Emirates Dirham
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
Japanese Yen
Saudi Riyal
People: